Skip Navigation

Cardiovascular Research 2004 61(2):227-237; doi:10.1016/j.cardiores.2003.11.026
© 2004 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Galié, N.
Right arrow Articles by Branzi, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Galié, N.
Right arrow Articles by Branzi, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2004, European Society of Cardiology

The endothelin system in pulmonary arterial hypertension

Nazzareno Galié*, Alessandra Manes and Angelo Branzi

Institute of Cardiology, University of Bologna, via Massarent 9, 40138-Bologna, Italy

* Corresponding author. Tel.: +39-051-349858; fax: +39-051-344859. n.galie{at}bo.nettuno.it

Endothelin-1 (ET-1), a peptide produced primarily by vascular endothelial cells, was discovered in 1980 and it was characterized as a powerful vasoconstrictor and mitogen for smooth muscle. ET-1 binds to two types of receptors, ETA and ETB: ETA-receptors are found in smooth muscle cells, whereas ETB-receptors are localized on both endothelial cells and in smooth muscle cells. Activation of ETA- and ETB-receptors on smooth muscle cells mediates the vasoconstrictive and mitogenic effects of ET-1. Stimulation of endothelial ETB-receptors promotes ET-1 clearance and activation of NO and prostacyclin release. Pulmonary arterial hypertension (PAH) is a severe condition characterized by a progressive increase in pulmonary vascular resistance leading to right ventricular failure and death. An activation of the ET-1 system has been demonstrated in both plasma and lung tissues of PAH patients as well as in animal models of PAH. The most efficient way to antagonize the ET-1 system is the use of ET-1 receptor antagonists that can block either ETA- or ETA- and ETB-receptors. These drugs are effective in animal models of PAH and have been tested in multiple clinical trials in patients with PAH. Bosentan, an orally active, dual ET-1 receptor antagonist has been shown to improve symptoms, exercise capacity, hemodynamics, echocardiographic parameters and the outcome of patients with severe PAH, and it has been approved for clinical use in many countries. The selective ETA-receptor antagonist sitaxentan has improved exercise capacity and hemodynamics of PAH patients in two preliminary studies. The main side effect of ET-1 antagonists is the increase of liver enzymes likely due to an accumulation of bile salts cytotoxic to hepatocytes. Additional trials with these drugs are currently ongoing. In conclusion, the hypothesis that the ET-1 system over-activation can be successfully antagonised in patients with PAH has been clearly demonstrated.

KEYWORDS Pulmonary circulation; Endothelins; Endothelial function; Endothelial receptors; Vasoconstriction/dilation

Time for primary review 28 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JNMHome page
W. B. Mathews, N. Murugesan, J. Xia, U. Scheffel, J. Hilton, H. T. Ravert, R. F. Dannals, and Z. Szabo
Synthesis and In Vivo Evaluation of Novel PET Radioligands for Imaging the Endothelin-A Receptor
J. Nucl. Med., September 1, 2008; 49(9): 1529 - 1536.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
T. L. Thai and W. J. Arendshorst
ADP-ribosyl cyclase and ryanodine receptors mediate endothelin ETA and ETB receptor-induced renal vasoconstriction in vivo
Am J Physiol Renal Physiol, August 1, 2008; 295(2): F360 - F368.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
F Iannone, M T Riccardi, S Guiducci, R Bizzoca, M Cinelli, M Matucci-Cerinic, and G Lapadula
Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension
Ann Rheum Dis, August 1, 2008; 67(8): 1121 - 1126.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
N. Galie, H. Olschewski, R. J. Oudiz, F. Torres, A. Frost, H. A. Ghofrani, D. B. Badesch, M. D. McGoon, V. V. McLaughlin, E. B. Roecker, et al.
Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2
Circulation, June 10, 2008; 117(23): 3010 - 3019.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
J. Behr and J. H. Ryu
Pulmonary hypertension in interstitial lung disease
Eur. Respir. J., June 1, 2008; 31(6): 1357 - 1367.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
H. H. Leuchte, T. Meis, M. El-Nounou, J. Michalek, and J. Behr
Inhalation of endothelin receptor blockers in pulmonary hypertension
Am J Physiol Lung Cell Mol Physiol, April 1, 2008; 294(4): L772 - L777.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.